Dr Reddy s Laboratories along with its subsidiaries announced the launch of Fluphenazine Hydrochloride Tablets, USP, in the U.S. market.
The company along with its subsidiaries today announced the launch of Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, approved by the U.S. Food and Drug Administration (USFDA).
The Prolixin brand and generic had U.S. sales of approximately $134 million MAT for the most recent twelve months ending in December 2020 according to IQVIA Health.
Dr Reddy s Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.
Domestic indices declined for third consecutive trading session on selling pressure in index pivotals. The Nifty slipped below the 15,100 mark in intraday trade but managed to close above that level. Negative cues from Asian markets impacted sentiment.
As per the provisional closing data, the barometer index, the S&P BSE Sensex, dropped 379.14 points or 0.73% at 51,324.07. The Nifty 50 index fell 89.95 points or 0.59% at 15,118.35.
The broader market outperformed the benchmark indices. The S&P BSE Mid-Cap index rose 0.69% while the S&P BSE Small-Cap index gained 0.67%.
The market breadth, indicating the overall health of the market, was positive. On the BSE, 1,639 shares rose and 1,328 shares fell. A total of 158 shares were unchanged.
Food and Drug Administration (USFDA).
The Prolixin brand and generic had U. S. sales of approximately $134 million MAT for the most recent twelve months ending in December 2020 according to IQVIA Health.
Dr. Reddy s Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and
10 mg tablets in 100 bottle count sizes.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with c
Read more about Healthcare stocks slide on Business Standard. Healthcare stocks were trading in red, with the S&P BSE Healthcare index decreasing 229.34 points or 1.04% at 21803.98 at 13:48 IST.
Read more about Sensex slips over 300 pts; Nifty trades near 15,200 mark on Business Standard. Equity benchmark indices tumbled in afternoon trade as selling pressure intensified. The Nifty was hovering near 15,200 mark. Indices witnessed profit selling after recent steep gains. Pharma and IT shares were under selling pressure.